Translating GLP-1RA trial outcomes to cardiology practice: Which patients will benefit?

10' education - Dec. 10, 2018 - Prof. Lars Rydén, MD - Stockholm Sweden - Online CME

Video navigation menu

Expected effects of incretin-based therapies for T2DM 0:32
Looking at the exendin-4-based GLP-1RA trial data in detail 2:48
Scrutinizing the study characteristics of the human analogue GLP-1RA trial data 5:19
What can explain the differences seen between trials testing various GLP-1RAs? 16:49
Impact of GLP-1RA on guidelines 18:30

Educational information

This lecture was part of a CME accredited symposium: 'Outcomes of GLP-1 RA in Diabetes & CVD: What are the key opportunities for cardiology practice?', held during ESC 2018 in Munich, Germany.

Faculty

Professor Lars Rydén, MD - Senior Professor of Cardiology, Karolinska Institute, Stockholm, Sweden

Disclosures

This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk

View slides of prof. Lars Rydén

Online-CME

This is available as accredited online CME for members. Click the button below to enroll:

Enroll

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.